Amarin Corporation will conduct a conference call on May 7, 2025, to discuss Q1 financial results.
Quiver AI Summary
Amarin Corporation plc announced that it will hold a conference call on May 7th, 2025, at 8:00 a.m. ET to discuss its first quarter 2025 financial results and address questions from investors. This call will take place following the release of the financial results earlier that morning. Interested parties can access the live call through Amarin's website or by dialing designated phone numbers, with a replay available afterward. Amarin, a pharmaceutical company focused on cardiovascular disease management, aims to enhance understanding and treatment of cardiovascular risks beyond conventional therapies. The company encourages stakeholders to stay informed through its investor relations resources, which include its website and other communication channels.
Potential Positives
- Amarin will provide insights into its first quarter 2025 financial results through a scheduled conference call, promoting transparency and engagement with investors.
- The company emphasizes its commitment to advancing cardiovascular disease management, highlighting its innovative approach and leadership in the pharmaceutical sector.
- The accessibility of the conference call and its replay through multiple channels demonstrates Amarin's dedication to keeping stakeholders informed and engaged.
Potential Negatives
- The announcement of an upcoming conference call to discuss quarterly results may indicate that the company is facing pressure to communicate its performance, possibly due to market or investor concerns.
- The need for a Q&A session may imply that there are significant uncertainties or challenges within the company that investors are keen to address.
- The timing of the earnings release in the pre-market hours could suggest the company is managing expectations regarding potentially disappointing financial results.
FAQ
When is Amarin's Q1 2025 results conference call?
Amarin's Q1 2025 results conference call is scheduled for May 7th, 2025, at 8:00 a.m. ET.
How can I access the live conference call?
You can access the live call by visiting Amarin's investor relations section at www.amarincorp.com or by dialing in.
What is the replay access information for the call?
The replay can be accessed by calling 877-481-4010 within the U.S. or 919-882-2331 internationally.
Where can I find more information about Amarin?
More information about Amarin can be found on their official website at www.amarincorp.com and their investor relations page.
Who should I contact for media inquiries?
For media inquiries, you can contact Mark Marmur at Amarin Corporation via [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AMRN Hedge Fund Activity
We have seen 46 institutional investors add shares of $AMRN stock to their portfolio, and 68 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY added 1,860,670 shares (+73.1%) to their portfolio in Q4 2024, for an estimated $902,424
- EVERSEPT PARTNERS, LP removed 1,792,717 shares (-54.2%) from their portfolio in Q4 2024, for an estimated $869,467
- ACADIAN ASSET MANAGEMENT LLC added 1,522,786 shares (+579.0%) to their portfolio in Q4 2024, for an estimated $738,551
- GSA CAPITAL PARTNERS LLP added 1,097,040 shares (+inf%) to their portfolio in Q4 2024, for an estimated $532,064
- AXA S.A. added 989,359 shares (+inf%) to their portfolio in Q4 2024, for an estimated $479,839
- LONGITUDE (CAYMAN) LTD. removed 750,000 shares (-31.6%) from their portfolio in Q4 2024, for an estimated $363,750
- QUINN OPPORTUNITY PARTNERS LLC added 508,989 shares (+85.2%) to their portfolio in Q4 2024, for an estimated $246,859
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its first quarter 2025 results followed by Q&A on Wednesday, May 7 th , 2025, at 8:00 a.m. ET.
The conference call with management will follow the release of the Company’s first quarter 2025 financial results in the pre-market hours on May 7 th .
Conference Call and Webcast Information:
Access to the live call:
Go to the investor relations section of the Company's website at
www.amarincorp.com
Dial in within the United States: 888-506-0062
International dial in: 973-528-0011
Access Code: 253130
Access to replay:
Dial in within the United States: 877-481-4010
International dial in: 919-882-2331
Access Code: 52230
A replay of the call will also be available through the Company's website shortly after the call.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (
www.amarincorp.com
) and the investor relations website (
http://www.amarincorp.com/investor-relations
), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor & Media Inquiries:
Mark Marmur
Amarin Corporation plc
[email protected]
[email protected]
